Inclisiran (Leqvio) During Pregnancy and Lactation: What the Evidence Actually Shows

Leqvio (inclisiran) is a small interfering RNA (siRNA) medication that reduces LDL cholesterol by suppressing PCSK9 gene expression within hepatocytes. The FDA has approved inclisiran as an add-on treatment to diet and high-dose statin therapy for adult patients with primary hyperlipidemia or a history of cardiovascular events. Inclisiran carries no FDA approval for pregnancy, and prescribing information indicates insufficient human pregnancy data to assess potential fetal effects. Unlike the monoclonal antibody PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent), inclisiran targets an earlier step in the PCSK9 pathway and has a longer duration of action in the body.

The direct answer

Inclisiran has not been studied in pregnant or lactating people, and the FDA label for Leqvio explicitly states there are insufficient data to evaluate drug-associated risk of major birth defects or miscarriage. Animal studies in rats and rabbits, conducted at exposures well above the human therapeutic dose, did not show teratogenic effects, but current cardiology and lipid guidelines still recommend discontinuing all lipid-lowering therapy, including inclisiran, before or immediately upon confirmation of pregnancy. The unresolved practical question for people of reproductive age is timing: because a single inclisiran injection suppresses PCSK9 production for roughly six months, conception soon after a dose means the drug's pharmacologic effect will still be active through much of the first trimester even though the drug itself has cleared from the bloodstream.

How inclisiran works, and why the pregnancy question is different from statins

Inclisiran is a synthetic siRNA conjugated to N-acetylgalactosamine (GalNAc), a sugar ligand that binds the asialoglycoprotein receptor found almost exclusively on liver cells. Once inside the hepatocyte, the siRNA is loaded into the RNA-induced silencing complex (RISC), which degrades the messenger RNA that codes for PCSK9. Less PCSK9 protein means more LDL receptors stay on the liver cell surface, and the liver clears more LDL cholesterol from the blood.

This is mechanistically different from statins, which block cholesterol synthesis (HMG-CoA reductase inhibition), and from evolocumab or alirocumab, which are antibodies that mop up PCSK9 protein after it is already in the bloodstream. The distinction matters for reproductive planning: inclisiran's plasma half-life is short, on the order of hours, but the RISC complex it loads into liver cells keeps suppressing PCSK9 for months after the injected drug itself is gone. That prolonged pharmacodynamic tail, not the plasma half-life, is what determines how long the biological effect lasts in the body, including through an early pregnancy that begins after the drug appears to have cleared.

What the FDA label actually says

The Leqvio prescribing information states that there are no data on inclisiran use in pregnant women to evaluate drug-associated risk. It does not assign a legacy pregnancy letter category (A, B, C, D, X) because the drug was approved in December 2021, after the FDA's 2015 Pregnancy and Lactation Labeling Rule replaced the letter system with narrative risk summaries. Readers can review the current label and any updates directly through the FDA's Drugs@FDA database.

The label also summarizes animal reproductive toxicology: in embryo-fetal development studies in rats and rabbits, subcutaneous inclisiran given during organogenesis at doses producing maternal exposures well above the human recommended dose did not produce teratogenicity or embryo-fetal toxicity. A pre- and postnatal development study in rats reported no adverse effects on offspring growth, survival, or developmental milestones at comparable exposure multiples. A fertility study in rats reportedly showed no effect on mating behavior or fertility indices at high doses. These findings come from the manufacturer's nonclinical toxicology package submitted to the FDA. The exact numeric exposure multiples and study design details should be verified against the current FDA label or pharmacology review before being cited as precise figures, since the specific published sources for these study results were not independently confirmed for this article.

Animal reproductive data of this kind reduce concern but do not establish human safety. Negative findings in rats and rabbits at supratherapeutic doses are reassuring as a screening step, not as a substitute for controlled or observational human pregnancy data, which do not yet exist for this drug class of hepatocyte-targeted siRNA therapeutics.

Why cholesterol biology in pregnancy makes this more than a routine "no data" situation

Normal pregnancy causes a substantial rise in maternal cholesterol. Total cholesterol and LDL-C increase over the course of gestation as part of a physiological adaptation that supports placental steroid hormone production and fetal membrane synthesis. Cholesterol is a required substrate for fetal cell membranes, for hedgehog signaling pathways involved in embryonic patterning, and for placental steroidogenesis. Smith-Lemli-Opitz syndrome, a genetic disorder of cholesterol biosynthesis, is a well-documented example of how severe fetal cholesterol deficiency causes serious malformations, though this is a distinct clinical situation from maternal LDL-lowering therapy and should not be read as direct evidence of drug-induced harm.

PCSK9 concentrations also rise during normal pregnancy, and some researchers have hypothesized that this supports the gestational increase in maternal cholesterol available to the fetal-placental unit. Because inclisiran works by suppressing PCSK9, there is a biologically plausible concern that treatment during pregnancy could blunt this adaptation and reduce cholesterol available to the fetus. This concern is theoretical. It has not been tested or observed in human pregnancies, and it should not be presented as an established risk. It is the same reasoning that historically supported the strict statin contraindication in pregnancy, a contraindication the FDA loosened in 2021 after reviewing observational data on statin exposures that did not show a consistent pattern of birth defects (see the FDA's 2021 safety communication). That history is a caution against overreading animal reassurance in either direction: the original statin contraindication turned out to be overstated, but that does not mean every LDL-lowering mechanism carries the same risk profile, and inclisiran's silencing mechanism has not been through the same volume of human exposure review that eventually softened the statin warning.

The following is the core, self-contained takeaway for this page: inclisiran has no FDA-approved use in pregnancy or lactation, no human pregnancy or breastfeeding data exist as of this writing, animal studies at high dose multiples did not show teratogenicity, and guideline bodies recommend stopping it before conception given the absence of human safety data and its unusually long duration of pharmacologic effect (roughly six months per dose). This combination of preclinical reassurance and total human data absence, paired with a long washout requirement, is what distinguishes inclisiran from shorter-acting lipid drugs in preconception counseling.

Should you stop inclisiran before trying to conceive, and how long is the washout?

Because a single 284 mg injection suppresses hepatic PCSK9 production for approximately six months, a person who receives a dose and conceives a few weeks later will still be under active PCSK9 silencing through most of the first trimester, even though the injected drug itself is no longer detectable in plasma within days. There is no formally specified washout period in the FDA label. Based on the drug's known duration of pharmacodynamic effect, the general clinical approach discussed among reproductive cardiology and lipid specialists is to plan the last inclisiran dose at least six months before attempting conception, allowing hepatic PCSK9 synthesis to recover before pregnancy begins. This is a matter of clinical judgment extrapolated from the drug's known duration of action, not a formal guideline-mandated number, and individual timing should be discussed with the prescribing clinician.

For comparison, evolocumab and alirocumab have elimination half-lives measured in days (roughly 11 to 17 days), giving a conventional five-half-life pharmacokinetic washout of about two to three months. Inclisiran's effective washout is longer because its rate-limiting step is intracellular RISC activity, not plasma clearance. People of reproductive potential using inclisiran should use reliable contraception during treatment and are generally advised to continue it for several months after the last dose, consistent with the drug's prolonged pharmacodynamic tail.

Can you breastfeed while using Leqvio?

There are no data on whether inclisiran passes into human breast milk, and no data on effects on a breastfed infant or on milk production. No lactation studies have been published in this population. Some clinicians point to physicochemical reasoning to argue exposure risk is likely low: GalNAc-siRNA conjugates are large molecules, and siRNA is not orally bioavailable because gut nucleases would degrade it before absorption even if it were present in milk. This reasoning is plausible but unproven; it has not been confirmed with actual milk-transfer studies for inclisiran. The American College of Obstetricians and Gynecologists has not published specific guidance on inclisiran during lactation; general information on medication use during pregnancy and breastfeeding is available through ACOG.

Most clinicians take the position that lipid-lowering therapy can be deferred during a time-limited period of breastfeeding, since the cardiovascular risk from a temporary rise in LDL-C over months is low for most patients. The calculation may differ for patients with homozygous familial hypercholesterolemia and very high baseline LDL-C, where treatment gaps carry a more immediate risk; these situations call for individualized shared decision-making between the patient, cardiologist, and obstetric team rather than a blanket rule.

What are the alternatives during pregnancy?

Guideline bodies (ACC/AHA and ESC/EAS lipid management guidelines) recommend against using statins, ezetimibe, PCSK9 monoclonal antibodies, or inclisiran during pregnancy, and describe bile acid sequestrants as the one lipid-lowering drug class with an established history of use in pregnancy, because they act within the intestinal lumen and are not absorbed systemically. Cholestyramine, colestipol, and colesevelam fall in this category, with colesevelam generally preferred for better gastrointestinal tolerability. A Cochrane review of interventions for familial hypercholesterolemia notes that even sequestrants lack randomized trial data specific to pregnant populations, but decades of clinical use without reported fetal toxicity provide reasonable reassurance (see the Cochrane Library for current systematic reviews on this topic). For patients with severe familial hypercholesterolemia, LDL apheresis, which mechanically removes LDL particles from plasma without drug exposure, is used at some centers throughout pregnancy.

The exact wording and scope of current ACC/AHA and ESC/EAS lipid guideline statements on inclisiran specifically should be checked against the most recent published guideline text, since inclisiran postdates some earlier guideline editions and specific society recommendations on it may be inferred from general PCSK9-therapy guidance rather than stated by name.

If pregnancy is discovered during inclisiran treatment

Stop further injections. The already-administered dose cannot be reversed or removed, and there is no established additional monitoring specifically indicated because of inclisiran exposure beyond standard first-trimester obstetric care, given the absence of a teratogenic signal in animal data. A lipid panel at baseline and through pregnancy can help guide whether a bile acid sequestrant is needed. Report the exposure to the manufacturer's pregnancy registry, referenced in the Leqvio prescribing information, and to the FDA's MedWatch program. Registries and spontaneous reports are currently the only mechanism by which human pregnancy outcome data on inclisiran will accumulate, since no clinical trials enroll pregnant participants for ethical reasons.

What is established, what is plausible, and what is not established

Established: Inclisiran has no FDA-approved indication in pregnancy or lactation. Human pregnancy and lactation data do not exist. The FDA label reports no teratogenicity signal in animal reproductive studies at high exposure multiples. A single dose suppresses PCSK9 for a duration measured in months, not days.

Plausible but unproven: That suppressing maternal PCSK9 during pregnancy could reduce cholesterol delivery to the fetal-placental unit in a clinically meaningful way. That the drug's large molecular size and lack of oral bioavailability make clinically significant transfer into breast milk unlikely.

Not established: Any specific level of human fetal risk, any specific numeric washout period backed by clinical trial data, and any confirmed absence or presence of the drug in human breast milk. Claims that state a precise risk percentage or a guideline-mandated washout interval for inclisiner specifically should be treated with caution until traced to the current FDA label or a named guideline document.

Decision framework: inclisiran and reproductive planning

This table is a planning aid built from the evidence summarized above. It is not a substitute for individualized medical advice, and specific timing decisions should be made with a clinician familiar with the patient's cardiovascular risk and pregnancy plans.